Sitagliptina, un inhibidor de la enzima DPP-IV, aumenta el colesterol plasmático total, altera el perfil de colesterol lipoproteico y disminuye el transporte reverso de colesterol en ratones

Simple item page
dc.contributor.authorLeiva, A.
dc.contributor.authorVaras, P.
dc.contributor.authorAmigo, L.
dc.contributor.authorContreras-Duarte, S.
dc.contributor.authorMaíz, A.
dc.contributor.authorRigotti Rivera, Attilio
dc.date.accessioned2020-01-12T03:02:00Z
dc.date.available2020-01-12T03:02:00Z
dc.date.issued2010
dc.description.abstractBackground: Insulin and glucagon regúlate the expression of key lipoprotein metabolism enzymes. Dyslipidemia is a significant risk factor for cardiovascular disease, the main cause of death in diabetic patients. Sitagliptine, an inhibitor of type IV dipep-tidil-peptidase (DPP-IV), controlling the metabolism of incretins, is a new hypoglycemic agent used for treatment of type II diabetes. Its effects on lipid metabolism are not clearly defined. Aim: to study the effects of sitagliptine upon parameters of cholesterol metabolism in mice. Methods: C5BL6/J mice were assigned to receive ei-ther a standard diet or one with sitagliptine supplemen-tation (0.6% P/P) for 8 weeks. DPP-IV plasma, total and lipoprotein cholesterol were measured using enzyme methods. Reverse cholesterol transport was evaluated through the peritoneal injection of cholesterol loaded macrophages followed by measurement of plasma and fecall4C labeled cholesterol. Results: compared to controls, sitagliptine treated mice exhibited a 38% decrease in plasma DPP-IV Total plasma cholesterol increased by 60% with a marked increase in HDL cholesterol. Also, an increased HDL cholesterol recovered from plasma along with a 30% decrease in fecal cholesterol was observed Finally, sitagliptine admi-nistration was associated to a decreased LDL and SR-BI hepatic receptors. Conclusión: Sitagliptine administration is associated to increased levéis of plasma cholesterol, mainly the HDL fraction, and decreased reverse cholesterol transport and fecal excretion. This effects seem to be mediated by a decreased expression of SR-BI in the liver. The expected increase in atherosclerosis associated to the atherogenic changes induced by sitagliptine should be the subject for further studies in mice.
dc.format.extent9 páginas
dc.fuente.origenFacultad de Medicina
dc.identifier.doi10.4067/S0718-85602010000300009
dc.identifier.issn0718-8560
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/27336
dc.issue.numeroNo. 3
dc.language.isoes
dc.pagina.final350
dc.pagina.inicio342
dc.revistaRevista chilena de cardiologíaes_ES
dc.rightsacceso restringido
dc.subjectSitaglipinees_ES
dc.subjectcholesteroles_ES
dc.subjectmicees_ES
dc.subjectCardiac & Cardiovascular Systems |es_ES
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.titleSitagliptina, un inhibidor de la enzima DPP-IV, aumenta el colesterol plasmático total, altera el perfil de colesterol lipoproteico y disminuye el transporte reverso de colesterol en ratoneses_ES
dc.typeartículo
dc.volumenVol. 29
sipa.codpersvinculados3362
sipa.codpersvinculados149064
sipa.codpersvinculados68489
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Sitagliptina, un inhibidor de la enzima DPP-IV, aumenta el colesterol plasmático total, altera el perfil de colesterol lipoproteico y disminuye el transporte reverso de colesterol en ratones.pdf
Size:
1.12 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas